Nationwide Fund Advisors’s KalVista Pharmaceuticals KALV Stock Holding History

Nationwide Fund Advisors’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-560	Closed	-$5K	–	3285
2016 Q1	$5K	Hold	560	–	–	﹤0.01%	3201
2015 Q4	$28K	Hold	560	–	–	﹤0.01%	3048
2015 Q3	$28K	Hold	560	–	–	﹤0.01%	3095
2015 Q2	$56K	Buy	+560	New	+$55.6K	﹤0.01%	3094

Other funds holding KALV

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Emerald Acquisition Seattle, Washington $51.8B AUM

First Quadrant Glendale, California $18M AUM 24.2% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

AFG

Albion Financial Group Salt Lake City, Utah $1.73B AUM 20.99% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

TD Asset Management Toronto, Ontario, Canada $123B AUM 34.51% 1-Year Est. Return

Nationwide Fund Advisors's KALV Position: Q2 2016 in Review

Nationwide Fund Advisors sold out of KalVista Pharmaceuticals (KALV) in Q2 2016, closing a stake of 560 shares — an estimated $5K sold.

Nationwide Fund Advisors first reported a position in KALV in Q2 2015 and held it in 4 quarters. The position peaked at $56K in Q2 2015. 32 funds tracked by Wall St. Rank hold KALV as of Q2 2016.

Nationwide Fund Advisors reported no remaining KalVista Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
Nationwide Fund Advisors sold 560 KalVista Pharmaceuticals shares in Q2 2016, an estimated $5K.
Nationwide Fund Advisors first reported a position in KalVista Pharmaceuticals in Q2 2015 and held it in 4 quarters.
Nationwide Fund Advisors's KalVista Pharmaceuticals position peaked at $56K in Q2 2015.
32 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2016.

Based on Nationwide Fund Advisors's 13F filing for Q2 2016, filed 9 Aug 2016.